Brokerages expect Insulet Co. (NASDAQ:PODD) to report sales of $197.79 million for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Insulet’s earnings, with estimates ranging from $197.00 million to $198.70 million. Insulet posted sales of $164.91 million during the same quarter last year, which indicates a positive year-over-year growth rate of 19.9%. The business is expected to issue its next earnings results on Monday, February 24th.
According to Zacks, analysts expect that Insulet will report full year sales of $726.77 million for the current year, with estimates ranging from $725.80 million to $728.21 million. For the next financial year, analysts expect that the company will post sales of $865.16 million, with estimates ranging from $792.42 million to $889.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Insulet.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Insulet had a return on equity of 10.34% and a net margin of 2.38%. The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. Insulet’s revenue was up 27.2% compared to the same quarter last year.
Several brokerages have recently issued reports on PODD. cut shares of Insulet from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. raised their price target on shares of Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday. BidaskClub lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 11th. Cowen set a $165.00 price objective on shares of Insulet and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Morgan Stanley upped their price objective on shares of Insulet from $148.00 to $181.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Insulet has a consensus rating of “Hold” and an average target price of $158.82.
In other Insulet news, CEO Shacey Petrovic sold 689 shares of Insulet stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $145.69, for a total transaction of $100,380.41. Following the sale, the chief executive officer now directly owns 94,510 shares of the company’s stock, valued at approximately $13,769,161.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John A. Fallon sold 14,525 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $181.21, for a total value of $2,632,075.25. 3.50% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Vanguard Group Inc. grew its stake in Insulet by 0.5% in the second quarter. Vanguard Group Inc. now owns 5,284,289 shares of the medical instruments supplier’s stock worth $630,838,000 after purchasing an additional 24,197 shares during the period. William Blair Investment Management LLC grew its position in shares of Insulet by 8.8% in the 2nd quarter. William Blair Investment Management LLC now owns 2,334,135 shares of the medical instruments supplier’s stock worth $278,649,000 after buying an additional 189,147 shares during the period. JPMorgan Chase & Co. grew its position in shares of Insulet by 5.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,619,136 shares of the medical instruments supplier’s stock worth $188,808,000 after buying an additional 88,440 shares during the period. Marshall Wace North America L.P. bought a new position in shares of Insulet in the 2nd quarter worth about $87,481,000. Finally, Eagle Asset Management Inc. increased its stake in shares of Insulet by 86.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 709,266 shares of the medical instruments supplier’s stock worth $116,979,000 after acquiring an additional 328,620 shares in the last quarter.
NASDAQ:PODD opened at $172.88 on Friday. The firm has a market cap of $10.54 billion, a PE ratio of 3,457.60 and a beta of 1.04. Insulet has a fifty-two week low of $70.80 and a fifty-two week high of $187.25. The company has a debt-to-equity ratio of 6.55, a quick ratio of 6.21 and a current ratio of 7.01. The business has a 50 day moving average price of $174.31 and a 200-day moving average price of $147.23.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with .